A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Ivonne Z. Jiménez‐Velázquez et al.|Nature Medicine|2021Cited by 364
Disease staging of Alzheimer’s disease using a CSF-based biomarker modelGemma Salvadó, Oskar Hansson, Tammie L.S. Benzinger et al.|Nature Aging|2024Cited by 108
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsNoëlle Warmenhoven, Oskar Hansson, Tammie L.S. Benzinger et al.|Brain|2024Cited by 95
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Tammie L.S. Benzinger et al.|The Lancet Neurology|2025Cited by 39